Cargando…

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?

Asciminib is a novel tyrosine kinase inhibitor (TKI) that specifically targets the myristoyl pocket. It has increased selectivity and potent activity against BCR-ABL1 and the mutants that most frequently prevent the activity of the ATP-binding competitive inhibitors. Results for clinical trials in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padala, Sandeep, Cortes, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Spotlight Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620583/ https://www.ncbi.nlm.nih.gov/pubmed/37102603 http://dx.doi.org/10.3324/haematol.2022.282361

Ejemplares similares

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
por: Hijiya, Nobuko, et al.
Publicado: (2023)

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
por: Luna, A., et al.
Publicado: (2022)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
por: Garcia-Gutiérrez, Valentín, et al.
Publicado: (2021)

PB2478: ASCIMINIB INDUCES ERYTHROPOIESIS IN CHRONIC MYELOID LEUKEMIA CELLS THROUGH DIFFERENTIATION AND NOT BY SELECTION
por: Hassan, Hammad, et al.
Publicado: (2023)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia
por: Tessier, Steven, et al.
Publicado: (2023)

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA
por: Bidikian, Aram, et al.
Publicado: (2023)

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
por: Kockerols, Camille C.B., et al.
Publicado: (2022)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
por: Tomassetti, Sarah, et al.
Publicado: (2022)

A TRCky TA protein delivery service snubs the UPS
por: McQuown, Alexander J., et al.
Publicado: (2021)

A high-throughput approach of screening nanoparticles for targeted delivery of mRNA
por: Khirallah, Jennifer, et al.
Publicado: (2023)

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
por: Réa, Delphine, et al.
Publicado: (2023)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

RNA and nanocarriers: next generation drug and delivery platform take center stage
por: Rouge, Jessica
Publicado: (2023)

P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
por: Breccia, Massimo, et al.
Publicado: (2023)

EXPEDITED MITRAL VALVE REPAIR USING ONE-STOP TEE DURING THE COVID-19 PANDEMIC
por: Okoh, Alexis K., et al.
Publicado: (2021)

The road ahead for chronic headache patients
por: Martelletti, P.
Publicado: (2006)

Reducing chronic disease may just be a walk in the park
por: Shapiro, Benjamin, et al.
Publicado: (2022)

Left ventricular lead delivery system used to implant right ventricular lead via persistent left superior vena cava
por: Yildiz, Bekir Serhat, et al.
Publicado: (2023)

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
por: Hughes, Timothy, et al.
Publicado: (2023)

P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
por: Atallah, Ehab, et al.
Publicado: (2023)

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
por: Atallah, Ehab, et al.
Publicado: (2023)

Facemasks as a COVID-19 barrier: a window into the overlooked experience of chronic dyspnoea?
por: Similowski, Thomas, et al.
Publicado: (2021)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Electroanatomic mapping in atrioventricular junction ablation during sinus rhythm for tachycardia‐bradycardia syndrome with persistent left superior vena cava
por: Wang, Norman C., et al.
Publicado: (2022)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2023)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
por: García-Gutiérrez, Valentin, et al.
Publicado: (2022)

STAMPing into Mitochondria
por: Yoo, Seong Keun, et al.
Publicado: (2014)

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors
por: Tesileanu, C Mircea S, et al.
Publicado: (2023)

Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos
por: Lin, Huan-Chau, et al.
Publicado: (2022)

P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Atallah, Ehab, et al.
Publicado: (2023)

Third-line therapy for chronic myeloid leukemia: current status and future directions
por: Cortes, Jorge, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mu1kd4v7k438dlp6k8gllrjq7v